Applicability of Uroflowmetry in Children With Cerebral Palsy
What is the Difference in the Applicability of the Uroflowmetry Between Children With Cerebral Palsy (CP) With Lower Urinary Tract Symptoms (LUTS) and Without Lower Urinary Tract Symptoms (LUTS)
Until now, the use of invasive urodynamics with use of catheters is still the gold standard for lower urinary tract evaluation in subjects with CP. This suggests a psychological and physical impact of invasive urodynamics in subjects with CP and further demonstrates the need to avoid standard use of invasive urodynamics in children and adults with CP.
The current study will evaluate usefulness of uroflowmetry, correlation between uroflowmetry parameters and different lower urinary tract symptoms will be investigated. Secondly, results of uroflowmetry indicating possible vulnerability of the upper urinary tract will be defined.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
A cross-sectional case-control study comparing children with CP and LUTS and children with CP without LUTS will be conducted with the primary objective to investigate correlation between uroflowmetry parameters and different LUTS.
Children will be evaluated with uroflowmetry and subsequent post void residual measurement and the validated vancouver symptom score for dysfunctional elimination syndrome.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Flanders
-
Ghent, Flanders, Belgium, 9000
- Ghent University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of cerebral palsy
- Dutch or French speaking child and parent
Exclusion Criteria:
- History of urological surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Standard toilet chair (hip angle 90°)
uroflow measurement with subsequent post void residual measurement, conducted on a standard toilet chair.
|
Non-invasive urodynamic measurement wireless uroflowmeter UROCAP™ IV, Goby System Laborie
Other Names:
Ultrasound of post void residual urine bladderscan CUBEscan BioCon 700
Other Names:
|
|
Experimental: Toilet chair with decreased hip angle
uroflow measurement with subsequent post void residual measurement, conducted on a toilet chair with decreased hip angle.
|
Non-invasive urodynamic measurement wireless uroflowmeter UROCAP™ IV, Goby System Laborie
Other Names:
Ultrasound of post void residual urine bladderscan CUBEscan BioCon 700
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Amount of pathological uroflow patterns - Qualitative assessment
Time Frame: During cross-sectional testing
|
Interpretation by pediatric urologist following ICCS classification Measured during uroflowmetry
|
During cross-sectional testing
|
|
Amount of pathological uroflow patterns - Quantitative assessment
Time Frame: During cross-sectional testing
|
Interpretation using Flow index methodology Measured during uroflowmetry
|
During cross-sectional testing
|
|
Maximal flow
Time Frame: During cross-sectional testing
|
Measured during uroflowmetry Qmax (mililitres/seconds
|
During cross-sectional testing
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Influencing factors for uroflow measurement
Time Frame: During cross-sectional testing
|
|
During cross-sectional testing
|
|
Voided volume
Time Frame: During cross-sectional testing
|
Measured during uroflowmetry mililitres Percentage of expected bladder capacity
|
During cross-sectional testing
|
|
Post void residual urine
Time Frame: During cross-sectional testing
|
Measured with CUBEscan BioCon 700 mililiters Percentage of voided volume
|
During cross-sectional testing
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Bieke Samijn, dr., Ghent University Hospital/Ghent University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BC-09774
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.